Skip to content
Regramostim
Regramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
705 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD008545233951362
LeukemiaD007938C95113771255
LymphomaD008223C85.9153841155
Prostatic neoplasmsD011471C61192931—43
NeuroblastomaD009447EFO_0000621102651442
Myeloid leukemia acuteD015470C92.0121731130
Non-hodgkin lymphomaD008228C85.93541215
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.03512—10
Covid-19D000086382U07.12411—7
Hematologic neoplasmsD01933722—126
Show 12 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5024333—254
Myelodysplastic syndromesD009190D4615204—235
Multiple myelomaD009101C90.012174—232
Hiv infectionsD015658EFO_0000764B201232—420
Plasma cell neoplasmsD0542196131——18
Pancreatic neoplasmsD010190EFO_0003860C25681—115
GlioblastomaD005909EFO_0000515671——14
SarcomaD012509272——11
Renal cell carcinomaD002292351——8
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340441——8
Show 27 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801523———34
Colorectal neoplasmsD015179915———19
Lung neoplasmsD008175C34.9079——218
Ovarian neoplasmsD010051EFO_0003893C56810——117
Non-small-cell lung carcinomaD002289310——113
Central nervous system neoplasmsD01654336———9
Kidney neoplasmsD007680EFO_0003865C6438———9
Fallopian tube neoplasmsD00518544———8
Liver neoplasmsD008113EFO_1001513C22.054———8
Myeloproliferative disordersD009196D47.135——18
Show 100 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G203————3
Rheumatoid arthritisD001172EFO_0000685M06.92————2
Kaposi sarcomaD012514C462————2
Wilms tumorD0093962————2
Diffuse intrinsic pontine gliomaD0000804432————2
MedulloblastomaD0085272————2
AstrocytomaD001254EFO_00002712————2
OligodendrogliomaD009837EFO_00006312————2
Biphenotypic leukemia acuteD015456C95.01————1
Coronary artery diseaseD003324I25.11————1
Show 30 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autologous transplantationD014182————22
Residual neoplasmD018365————11
Acute liver failureD017114————11
Multiple organ failureD009102EFO_1001373————11
InflammationD007249————11
EndotoxemiaD019446————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREGRAMOSTIM
INNregramostim
Description
Regramostim is a protein pharmaceutical. It is currently being investigated in clinical studies.
Classification
Protein
Drug classcolony-stimulating factors: granulocyte macrophage colony-stimulating factors (GM-CSF); colony-stimulating factors: macrophage colony-stimulating factors (M-CSF)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2107881
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDKR89Q40F01 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details